MDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues, Issues 2026 Revenue Guidance, and Amends Earnout Terms with Exact Sciences IRVINE, CA – January 12, 2026 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the “Company” or “mdxhealth”), a leading precision diagnostics company, today reported preliminary fourth quarter and full year 2025 revenues and issued 2026 revenue guidance. The Company expects to report fourth quarter and full year 2025 revenues of approximately $30.5 million and $109 million, respectively, representing year-over-year growth of 23% and 21%, respectively. During the fourth quarter, the Company billed 11,201 tissue-based units and 27,486 liquid-based units, representing year-over-year growth of (5%) and 128%, respectively, reflecting Q4 focus on integration of the Exosome...

Full year MRD revenue growth of 46% driven by clonoSEQ® testing volume SEATTLE, Jan. 12, 2026 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced preliminary, unaudited results for the fourth quarter and full year ended December 31, 2025.Total revenue for the fourth quarter and full year 2025 was approximately $72 million and $277 million, representing an increase of 51% and 55%, respectively, over the corresponding periods in 2024. MRD revenue for the fourth quarter and full year 2025 was approximately $62 million and $212 million, representing an increase of 54% and 46%, respectively, over the corresponding periods in 2024. Excluding...

Demonstrating continued revenue growth, operational efficiencies and positive cash flow MOUNTAIN VIEW, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) — Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced preliminary unaudited operational and financial results for the fourth quarter and full year ended January 3, 2026. Fourth Quarter 2025 ResultsTotal revenue is expected to be between $14.6 million and $14.8 million compared to $12.7 million in the prior year quarter, representing year-over-year growth between 15% and 17% Achieved positive cash flow in the fourth quarter Sold 15,800 Cyclo G6® probes compared to 13,300 in the prior year quarter Sold 44 Cyclo G6 Glaucoma...

Paris (France), January 12, 2026 Full-year 2025 financial updateRobust activity, with segment revenue expected to exceed $1,150 million, including more than $440 million in Geoscience (+10% year-on-year) and more than $400 million in Earth DataSolid cash flow generation above $130 million, resulting in Net Cash Flow for 2025 exceeding $100 million after repayment of the $28 million asset-backed facility related to the Group’s HPC infrastructureBond repayments totaling $97 million, fully utilizing the 10% annual optional redemption clause included in the bond documentationNet debt (pre-IFRS 16) expected to stand around $750 million at year-endSophie Zurquiyah, Chair and CEO of Viridien: “2025 marked another important milestone in the execution of our asset-light strategy and financial roadmap. We delivered solid operational performance...

Total Revenue of $55.9 million, up 35.3% year-over-year, marking a new record high in the Company’s history. Gross Profit of $22.5 million, reflecting continued investment in AI-native production capabilities. NON-GAAP Operating Income reached $10.8 million, representing a year-over-year increase of 17.9%. Strategic transition toward AI-native production and AI Agent–driven workflows accelerated during fiscal year 2025.BEIJING, Jan. 09, 2026 (GLOBE NEWSWIRE) — Global Mofy AI Limited (the “Company” or “Global Mofy”) (Nasdaq: GMM), a generative AI-driven technology solutions provider engaged in virtual content production and the development of 3D digital assets for use in the broader digital content industry, today announced its financial results for the fiscal year ended September 30, 2025. During fiscal year 2025, the Company...

INDIANAPOLIS, Jan. 09, 2026 (GLOBE NEWSWIRE) — Hurco Companies, Inc. (Nasdaq: HURC) today reported results for the fourth fiscal quarter and fiscal year ended October 31, 2025. Hurco recorded a net loss of $3,041,000, or $0.47 per diluted share, for the fourth quarter of fiscal year 2025, compared to a net loss of $1,442,000, or $0.23 per diluted share, for the corresponding period in fiscal year 2024. Hurco recorded a net loss of $15,117,000, or $2.34 per diluted share, for fiscal year 2025, compared to a net loss of $16,608,000, or $2.56 per diluted share, for fiscal year 2024. The recorded net losses for fiscal years 2025 and 2024, included non-cash tax valuation allowances of $4,778,000 and $8,590,000, respectively, recorded in provision for income taxes. Sales and service fees for the fourth quarter of fiscal year 2025 were...

Estimated YUTREPIA™ net product sales of approximately $90.1 million in the fourth quarter and $148.3 million for full-year 2025 Received more than 2,800 unique patient prescriptions since launch in June 2025 Generated more than $30 million of positive cash flow during the fourth quarter 2025MORRISVILLE, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced preliminary, unaudited full-year 2025 net product sales of YUTREPIA™ (treprostinil) inhalation powder, as well as updates on the commercial launch and the clinical pipeline. These updates will be discussed during Liquidia’s participation in the 44th Annual J.P. Morgan Healthcare...

Sanuwave is pleased to announce preliminary revenues of $13.3 million to $13.4 million for the fourth quarter ended December 31, 2025. This represents the highest quarterly revenues in Company history. Q4 2025 revenue increased between 29% and 30% compared to Q4 2024. Full Year 2025 revenue increased to $44.3-$44.4 million up 36% vs Full Year 2024. 2025 annual revenues were an all-time record for the Company. EDEN PRAIRIE, Minn., Jan. 09, 2026 (GLOBE NEWSWIRE) — Sanuwave Health, Inc. (the “Company” or “Sanuwave”) (NASDAQ: SNWV), a leading provider of FDA-approved directed energy systems used in advanced wound care, today announced that revenues for the fourth quarter of 2025 are expected to be in the range of $13.3 to $13.4 million, an increase of 29% to 30% over Q4 2024. This number is within the range of guidance...

Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Tecan reports return to sales growth and strong order entry in the second half of 2025Group sales of CHF 882.5 million, down 1.6% in local currencies for the year, with second-half sales growth of 0.4% Order entry increased by 3.8% in local currencies for the full year and by 8.6% in the second halfMännedorf, Switzerland, January 9, 2026 – In a trading statement, the Tecan Group (SIX Swiss Exchange: TECN) today published unaudited preliminary results for fiscal year 2025, reporting moderate sales growth and strong order entry in local currencies in the second half. For the full year, sales in local currencies were in line with the sales outlook last confirmed on October 13, 2025. Group sales for 2025 decreased by 1.6% in local currencies and 5.5%...

TORONTO, Jan. 08, 2026 (GLOBE NEWSWIRE) — Nexus Industrial REIT (“Nexus” or the “REIT”) (TSX: NXR.UN) announced today that it intends to release its financial results for the fourth quarter and year ended December 31, 2025, before the opening of the TSX on Friday, March 6, 2026. Management of the REIT will host a conference call at 10:00 AM Eastern Standard Time on Friday March 6, 2026, to review the financial results and operations. To participate in the conference call, please dial 1-647-846-8414 or 1-833-752-3601 (toll free in Canada and the US) at least five minutes prior to the start time and ask to join the Nexus Industrial REIT conference call. A recording of the conference call will be available until April 6, 2026. To access the recording, please dial 1-412-317-0088 or 1-855-669-9658 (toll free in Canada and...